argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 29 aug 2018 - 07:00
  • Statutory name argenx SE
  • Title argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis

Related downloads

201808290000000004_argenx receives feedback from Japan.docx

Date last update: 16 January 2021

Share information

Share on: Share this